PuraPharm Corporation Limited provided unaudited preliminary group earnings guidance for the full year ended December 31, 2019. Based on the preliminary review of the unaudited consolidated management accounts of the Group for the year ended December 31, 2019 and other information currently available to the Board, it is expected that the Group will record a net loss of not less than HKD 140 million for the year ended December 31, 2019, as compared to the audited consolidated net profit recorded in the year ended December 31, 2018 of approximately HKD 20.8 million.